Results for tag: "Kovaltry"

Kovaltry is a hematological drug developed by Bristol-Myers Squibb and marketed by Celgene Corporation. It is a recombinant humanized monoclonal antibody that binds to and inhibits the activity of Factor VIII, a protein involved in the clotting cascade. This drug is used to treat and prevent bleeding episodes in patients with hemophilia A, a genetic disorder in which the body does not produce enough Factor VIII. Kovaltry is the first and only recombinant humanized monoclonal antibody approved for the treatment of hemophilia A. It is administered as a subcutaneous injection and has been shown to reduce the frequency of bleeding episodes and improve quality of life for patients. The Kovaltry market is composed of a number of companies that produce and market drugs for the treatment of hemophilia A. These include Bristol-Myers Squibb, Celgene Corporation, Novo Nordisk, Pfizer, Bayer, and Shire. These companies are involved in the research, development, and marketing of Kovaltry and other drugs for the treatment of hemophilia A. Show Less Read more